Signs of compromise over Indonesian manufacturing rule
This article was originally published in Scrip
The Indonesian government has shown some signs of flexibility over a new regulation which is causing a headache for many foreign multinationals in the country, although it is not clear if or how it may be changed.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.